Markers of immune-related adverse events and applications thereof

An adverse reaction, immune-related technology, applied in the field of biomedicine to achieve the effect of improving the prognosis

Active Publication Date: 2020-10-02
BEIJING XINNUO WEIKANG TECH CO LTD
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been reported that T cell receptor (TCR) diversity, CD8+ T cell clonal expansion, and tumor burden mutation (TMB) have the potential to predict irAEs, but these conclusions were based on univariate analysis or were limited to a limited number of cases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Markers of immune-related adverse events and applications thereof
  • Markers of immune-related adverse events and applications thereof
  • Markers of immune-related adverse events and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] 1 Experimental method

[0031] (1.1) Data Analysis of FAERS Personal Safety Report

[0032] This invention is obtained from FAERS (https: / / www.fda.gov / drugs / questions-and-answers-fdas-adverse-event-

[0033] reporting-system-faers / fda-adverse-event-reporting-system-faers-public-dashboard) to obtain personal security reports from July 1, 2014 to June 30, 2019. Only patients treated with anti-PD-1 antibodies (nivolumab, pembrolizumab, similumab) and anti-PD-L1 (atezolizumab, avelumab, durvalumab) were collected Adverse reaction reports were reported, and patients who also received anti-CTLA-4 antibody therapy (ipilimumab, tremelimumab) were excluded. Use the peer-reviewed irAE management manual as a standard to define irAEs. An unbalanced analysis was adopted, and the entire database was used as a comparison sample to calculate the ROR of irAE risk. Patients who developed any type of irAE were included in the irAE group.

[0034] (1.2) Analysis of TCGA database and i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to markers of immune-related adverse events and applications thereof. The markers include LCP1 and / or ADPGK. Through the adoption of the biomarkers of the immune-related adverseevents and applications thereof, a kit and method for performing early prediction and active intervention on the immune-related adverse events caused by anti-PD-1 / PD-L1 antibody therapy can be provided, and therefore, the prognostic effects of patients can be enhanced.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a marker of immune-related adverse reactions and its application. Background technique [0002] Anti-programmed death 1 (PD-1) / anti-programmed death ligand 1 (PD-L1) antibody therapy activates the body's immune response and breaks immune homeostasis, The resulting immune-related adverse events (Immune-related adverse events, irAEs) will involve the whole body organs, and can lead to death in severe cases. Pneumonia is the most common fatal injury of irAEs, causing death in 10% of patients and accounting for 35% of anti-PD-1 / PD-L1 antibody treatment-related mortality. Myocarditis is the most important lethal injury of irAEs, with a mortality rate as high as 50%. Therefore, the discovery of irAEs biomarkers has a decisive role in the prediction of the therapeutic benefit-to-risk ratio in patients receiving anti-PD-1 / PD-L1 antibody therapy. Reports have shown that...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886
CPCG01N33/6893G01N2333/4712G01N2333/47
Inventor 薛新颖景莹庄光磊刘锦臧学磊高杰
Owner BEIJING XINNUO WEIKANG TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap